Drug Trial Radar · NCT04215653
A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
Last checked: Nov 19, 2026Latest source record: Jan 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
448
Planned (sponsor's estimate)
Start
Jan 20, 2020
Primary completion
Feb 15, 2021
Study completion Feb 28, 2021
Sponsor
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3,double-blinded, double dummy, parallel, non-inferiority, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD compared with rabeprazole 10mg QD in patients with duodenal ulcers.
Conditions
- Duodenal Ulcer,DU
Interventions
Anaprazole SodiumDrug
administered orally once every 30-60 minutes before breakfast for 4 weeks
RabeprazoleDrug
administered orally once every 30-60 minutes before breakfast for 4 weeks
Rabeprazole PlaceboDrug
administered orally once every 30-60 minutes before breakfast for 4 weeks
Anaprazole Sodium PlaceboDrug
administered orally once every 30-60 minutes before breakfast for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The endoscopic healing rate of duodenal ulcers at week 4, evaluated by blinded independency central reading.Time frame: Treatment of 4 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.